Specialists of the domestic pharmaceutical company Farmak have developed and brought to market a drug for the treatment of severe conditions, chronic cerebrovascular disorders and mental activity disorders – Gliaton (choline alfoscerate). The new drug is produced in the form of a solution for injection in 1000 mg ampoules No. 5.
Farmak is actively working in the sphere of treatment of cardiovascular diseases. In particular, much attention is given to ensure comprehensive effective and affordable treatment of severe and chronic cerebrovascular disorders and mental activity disorders. To achieve this objective, the company's specialists have developed and brought to market the drug product Gliaton (choline alfoscerate).
Gliaton is indicated in the acute phase of craniocerebral trauma, in impaired consciousness, coma, focal hemispheric symptoms; degenerative involutional psychoorganic syndromes, cerebrovascular insufficiency; primary and secondary mental disorders, memory impairment, confusion and disorientation. The drug is also indicated in emotional instability, irritability, indifference; pseudo melancholy in the elderly.
Gliaton is the drug that “awakens” (brings) patients out of comas, improves patients’ quality of life: improves memory, mental activity after injuries or as a result of cerebrovascular insufficiency.
The course of treatment with the drug is 2-3 weeks.
Taking into consideration the increased public interest in medical science, Liga.net and Farmak created a joint project that gives an idea of the current situation (and the situation over past 20 years) in the world medicine. 20 medical innovations which have been the most important in the 21st century were selected. The choice was […]
Farmak reported 2019 financial results. The performance of the Company remains at a consistently high level. According to IFRS-compliant financial statements, the amount of money spent on capital investment in 2019 was UAH 714 million, which is 14.5% more than at the end of 2018. The revenue of Farmak reached UAH 6.542 billion, net profit […]
Today, Kyiv City Clinical Hospital No. 9 and Kyiv City Children’s Clinical Hospital No. 1, where coronavirus patients are treated, have been equipped with CARDIOVIT AT-1 G2 ECG machine, DEFIGARD 4000 Defibrillator/Monitor, and IM-80 (2.0) patient monitor due to the assistance of the Zhebrivski Family Charitable Foundation. 13 medical specialists will be trai...